---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-243765"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:15:56.976209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Olema reports palazestrant + ribociclib Phase 1b/2 mPFS of 15.5 months in ER+/HER2- MBC

## Summary
- As of July 8, 2025, 72 patients enrolled across 90 mg and 120 mg palazestrant dose cohorts with ribociclib 600 mg.
- Median PFS for 120 mg cohort (56 patients) was 15.5 months for all; 12.2 months in prior CDK4/6i patients.
- In prior CDK4/6i patients, mPFS was 9.2 months (ESR1 wild-type) and 13.8 months (ESR1 mutant tumors).
- Combination well tolerated, no new safety signals, no drug-drug interactions, consistent with known profiles.
- Data support ongoing Phase 3 OPERA-02 trial evaluating palazestrant + ribociclib in frontline MBC.

## SEC filing metadata
- accession: 0001193125-25-243765
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312525243765/0001193125-25-243765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312525243765/olma-20251018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-243765
- JSON: https://secwatch.observer/filing/0001193125-25-243765.json
- Plain text: https://secwatch.observer/filing/0001193125-25-243765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.